new mexico news reporter

Delveinsight Business Research LLP

Some of the major pharma and biotech companies such as Otsuka Pharmaceuticals, Janssen Research & Development, Axsome Therapeutics, AbbVie, SAGE Therapeutics, Minerva Neurosciences, Luye Pharma, Relmada Therapeutics, BioLite Inc., VistaGen Therapeutics, Praxis Precision Medicines, Intra-Cellular Therapies, Neurocrine Biosciences, Arrivo Bioventures, Sirstei Pharmaceuticals, Alto Neuroscience, and others are actively working in the Major Depressive Disorder Market.

DelveInsight’s “Major Depressive Disorder Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Major Depressive Disorder market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The Major Depressive Disorder market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Major Depressive Disorder: An Overview

Major depressive disorder (MDD) is one of the most prevalent psychiatric disorders. It has been projected by the World Health Organization to be the leading cause of disease burden in high-income countries by 2032. Major depressive disorder is characterized by persistent sadness, loss of interest or pleasure, low energy, worse appetite and sleep, and even suicide, disrupting daily activities and psychosocial functions.

It is diagnosed when an individual has a persistently low or depressed mood, anhedonia or decreased interest in pleasurable activities, feelings of guilt or worthlessness, lack of energy, poor concentration, appetite changes, psychomotor retardation or agitation, sleep disturbances, or suicidal thoughts. As per the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5), an individual must have five of the above-mentioned symptoms, one of which must be a depressed mood or anhedonia causing social or occupational impairment, to be diagnosed with MDD.

Major Depressive Disorder Market Key Facts

• This section includes a glimpse of the major depressive disorder market in the 7MM. The major depressive disorder (MDD) market size in the seven major markets was approximately USD 5,600 million in 2021.

• In 2021, the total 12-month prevalent cases of major depressive disorder (MDD) in the 7MM exceeded 48 million, out of which the highest 12-month prevalent cases were observed in the United States. The EU5 countries accounted for more than 20 million cases as a whole in 2021.

• In 2021, there were about 4.8 million Refractory (or TRD) cases of MDD in the United States. The overall refractory cases of Major Depressive Disorder in the US are subject to increase in the coming years.

• The patient pool of females was higher than males in the United States.

Major Depressive Disorder Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current and forecasted Major Depressive Disorder market size by analyzing the impact of current and emerging pipeline therapies. It also thoroughly assesses the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete detail of the Major Depressive Disorder market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.

Major Depressive Disorder Epidemiology Assessment 

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and views of key opinion leaders. 

The Report Covers the Major Depressive Disorder Epidemiology, Segmented as –

• 12 Months Prevalent Cases of MDD in the 7MM [2019–2032]

• Severity-specific Cases of MDD in the 7MM [2019-2032]

• Gender-specific Prevalence of MDD in the 7MM [2019-2032]

• Refractory (or TRD) Cases of MDD in the 7MM [2019–2032]

Major Depressive Disorder Drugs Uptake and Pipeline Development Activities

The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Major Depressive Disorder market or expected to be launched during the study period. The analysis covers the Major Depressive Disorder market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Major Depressive Disorder pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Learn How the Major Depressive Disorder Market Will Evolve and Grow by 2032 @ 

https://www.delveinsight.com/sample-request/major-depressive-disorder-market

Major Depressive Disorder Therapeutics Analysis

The treatment strategies for depression consist of both pharmacological and non-pharmacological options, including psychotherapy, electroconvulsive therapy, and transcranial magnetic stimulation. In recent years, psychotherapy has been shown to affect depression, including attenuating depressive symptoms and improving quality of life. Therefore, several practice guidelines increasingly recommend psychotherapy as a monotherapy or in combination with antidepressants.

To improve the treatment scenario, several major pharma and biotech companies are developing therapies for Major Depressive Disorder. Currently, SAGE Therapeutics is leading the therapeutics market with its Major Depressive Disorder drug candidates in the most advanced stage of clinical development.

The Leading Players in the Major Depressive Disorder Therapeutics Market Include:

AbbVie, Alto Neuroscience, Arrivo Bioventures, Axsome Therapeutics, BioLite Inc., BlackThorn Therapeutics, Inc., Bristol-Myers Squibb, Chase Therapeutics, Fabre-Kramer Pharmaceuticals, Forest Laboratories, Gedeon Richter, GH Research, Intra-Cellular Therapies, Janssen Research & Development, Luye Pharma, Minerva Neurosciences, Neumora Therapeutics, Inc., Neurocrine Biosciences, Novartis, Otsuka Pharmaceutical Co., Ltd., Pherin Pharmaceuticals, Praxis Precision Medicines, Relmada Therapeutics, SAGE Therapeutics, Sirstei Pharmaceuticals, Takeda, Takeda Pharmaceuticals, VistaGen Therapeutics, and others.

Major Depressive Disorder Emerging and Marketed Drugs Covered in the Report Include:

• ABV-1504: BioLite Inc.

• ALTO-300: Alto Neuroscience

• AXS-05: Axsome Therapeutics

• Brintellix: Takeda Pharmaceuticals

• CAPLYTA (Lumateperone): Intra-Cellular Therapies

• CTC-501: Chase Therapeutics

• Fetzima: Forest Laboratories

• LY03005: Luye Pharma

• MIJ821: Novartis

• MIN-202 (Seltorexant): Janssen Pharmaceuticals/Minerva Neurosciences

• NBI-1065845: Neurocrine Biosciences

• NMRA-140: Neumora Therapeutics, Inc./BlackThorn Therapeutics, Inc.

• OPC-64005: Otsuka Pharmaceutical Co., Ltd.

• PDC-1421: BioLite Inc

• PRAX-114: Praxis Precision Medicines

• REL-1017: Relmada Therapeutics

• Rexulti: Otsuka Pharmaceuticals

• SAGE-217: Sage Therapeutics

• Seltorexant: Minerva Sciences

• SP-624: Arrivo Bioventures/Sirstei Pharmaceuticals

• SPL026: Small Pharma

• SPRAVATO (Esketamine): Janssen Research & Development

• Travivo: Fabre-Kramer Pharmaceuticals

• Vraylar (Cariprazine): AbbVie

• Zuranolone (SAGE-217/BIIB125): SAGE Therapeutics

And Many More

The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @

https://www.delveinsight.com/sample-request/major-depressive-disorder-market

Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Major Depressive Disorder Competitive Intelligence Analysis

4. Major Depressive Disorder Market Overview at a Glance

5. Major Depressive Disorder Disease Background and Overview

6. Major Depressive Disorder Patient Journey

7. Major Depressive Disorder Epidemiology and Patient Population (In the US, EU5, and Japan)

8. Major Depressive Disorder Treatment Algorithm, Current Treatment, and Medical Practices

9. Major Depressive Disorder Unmet Needs

10. Key Endpoints of Major Depressive Disorder Treatment

11. Major Depressive Disorder Marketed Products

12. Major Depressive Disorder Emerging Drugs and Latest Therapeutic Advances

13. Major Depressive Disorder Seven Major Market Analysis

14. Attribute Analysis

15. Major Depressive Disorder Market Outlook (In US, EU5, and Japan)

16. Major Depressive Disorder Access and Reimbursement Overview

17. KOL Views on the Major Depressive Disorder Market

18. Major Depressive Disorder Market Drivers

19. Major Depressive Disorder Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download the Sample PDF to Learn More About the Key Offerings of the Report @

https://www.delveinsight.com/sample-request/major-depressive-disorder-market

Connect with us and discover how Delveinsight can help you to identify your potential business partners and investors in the highly dynamic and evolving healthcare market today @ Healthcare Partner Identification Services

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/